Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended July 1, 2001, and the six months ended July 1, 2001, for PerkinElmer, Inc. (Note: The input metadata references "REVVITY, INC.", but the filing text explicitly identifies the registrant as PerkinElmer, Inc.). PerkinElmer is a global technology company operating in four segments: Life Sciences, Optoelectronics, Instruments, and Fluid Sciences. The company serves markets including drug discovery, genetic screening, telecommunications, and aerospace. During the period, the company classified its Security and Detection Systems business as a discontinued operation pending sale.
Key Financial Metrics
| Metric | Three Months Ended July 1, 2001 | Six Months Ended July 1, 2001 |
|---|---|---|
| Sales (Revenue) | $390.8 million | $795.3 million |
| Net Income | $29.4 million | $52.9 million |
| Diluted EPS (Net Income) | $0.28 | $0.51 |
| Operating Income (Continuing Ops) | $53.6 million | $104.7 million |
| Gross Margin | 44.8% | 43.8% |
| Cash and Cash Equivalents | $132.3 million | $132.3 million (Ending Balance) |
| Short-Term Debt | $228.9 million | $228.9 million |
| Long-Term Debt | $589.8 million | $589.8 million |
| Net Cash Provided by Operating Activities | N/A | $37.0 million |
Material Changes Versus Prior Period
- Revenue Growth: Sales increased 6% in the quarter and 7% year-to-date compared to the prior year periods. Organic revenue growth was 3% in the quarter, driven by Life Sciences (12% growth) and Instruments (9% growth), offset by declines in semiconductor and photography markets.
- Margin Expansion: Gross margins improved to 44.8% in the quarter (from 41.5%) and 43.8% year-to-date (from 40.5%), attributed to portfolio improvements and cost controls.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses as a percentage of sales increased to 27.2% in the quarter, primarily due to goodwill amortization from the NEN Life Sciences acquisition and integration costs.
- Discontinued Operations: The Security and Detection Systems business reported a net loss of $1.5 million for the quarter and $1.9 million for the six months, compared to net income of $1.1 million and a loss of $6.4 million in the prior year periods, respectively.
- Restructuring: The company recorded pre-tax restructuring credits of $2.5 million for the six months ended July 1, 2001, due to lower-than-anticipated costs in the Fluid Sciences segment.
Guidance, Outlook, and Risks
- Acquisition Activity: On July 16, 2001, the company announced a proposed acquisition of Packard BioScience Company, expected to close in the fourth quarter of 2001. The transaction will be accounted for as a purchase.
- Restructuring Outlook: The company expects to incur at least $20 million to $25 million in cash outlays for restructuring plans throughout fiscal 2001.
- Market Risks: The company faces exposure to foreign exchange rate fluctuations (primarily Euro, Yen, and British Pound) and interest rate changes. It utilizes derivative instruments to hedge these risks but notes that forecasting errors could lead to unanticipated gains or losses.
- Accounting Changes: The company is assessing the impact of new FASB standards (SFAS No. 141 and 142) regarding business combinations and goodwill, which will eliminate goodwill amortization for future acquisitions and change impairment testing procedures.
Investor Verification Checklist
- Verify the impact of the NEN Life Sciences acquisition on organic growth versus reported growth.
- Confirm the timeline and regulatory approval status for the proposed Packard BioScience acquisition.
- Monitor the execution of restructuring plans and the associated cash outlays ($20M-$25M expected for fiscal 2001).
- Review the performance of the Life Sciences segment, which showed significant revenue growth (85% quarter-over-quarter) driven by the NEN acquisition.
- Assess the company's exposure to foreign currency volatility given its international sales mix.